Piyasa Haberleri

En güncel finans ve ekonomi haberlerini, piyasa gelişmelerini, raporları ve analizleri PipVero’da takip edin.

Kaynak: Market Watch Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

The Danish company developed the most lucrative new drug the world had ever seen. Then America's Eli Lilly outmaneuvered it and took control of the diet-drug market.

İlgili Semboller 1
GLP GLP
Kaynak: Market Watch
Kaynağı Ziyaret Et
0 0 0
Devamını Oku
Yorum Yap
Kaynak: Seeking Alpha Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
HF Sinclair: In A Sweet Spot If Russian Supply Does Not Return

HF Sinclair: In A Sweet Spot If Russian Supply Does Not Return

HF Sinclair (DINO) is rated Buy, with 50% upside to a $133 price target, driven by sustained tightness in global refined products markets. DINO's diversified model, including midstream and marketing, buffers refining margin volatility; the upcoming lubricants spinoff provides additional upside potential. Consensus forecasts underestimate the duration of elevated crack spreads, assuming rapid normalization, while my base case expects prolonged high margins due to persistent geopolitical disruptions.

İlgili Semboller 1
DINO DINO
Kaynak: Seeking Alpha
Kaynağı Ziyaret Et
0 0 0
Devamını Oku
Yorum Yap
Kaynak: Proactive Investors Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
SolarEdge forecasts weaker Q3 as US residential market remains challenging

SolarEdge forecasts weaker Q3 as US residential market remains challenging

SolarEdge Technologies (NASDAQ:SEDG) shares fell about 24% on Wednesday after the solar technology company issued a weaker-than-expected third quarter outlook, overshadowing better-than-expected second quarter results. The company guided for Q3 2026 revenue of $310 million to $340 million, with a midpoint of $325 million, below analyst expectations of roughly $368 million to $372 million.

İlgili Semboller 1
SEDG SEDG
Kaynak: Proactive Investors
Kaynağı Ziyaret Et
Official Partner ITBFX Start Trading
0 0 0
Devamını Oku
Yorum Yap
Kaynak: Zacks Investment Research Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Can MRVL's Communications Recovery Drive Broad-Based Growth?

Can MRVL's Communications Recovery Drive Broad-Based Growth?

Marvell Technology's MRVL communications and other business segment has been recovering as customer inventories normalize. In the first quarter of fiscal 2027, communications and other revenues increased 29% year over year to $585 million.

İlgili Semboller 1
MRVL MRVL
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et
0 0 0
Devamını Oku
Yorum Yap
Kaynak: Zacks Investment Research Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Should Investors Buy Boston Scientific Stock Despite Near-Term Risks?

Should Investors Buy Boston Scientific Stock Despite Near-Term Risks?

Boston Scientific's cheaper valuation offers upside, but weaker guidance, share losses, higher debt and delayed catalysts favor patience.

İlgili Semboller 1
BSX BSX
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et
Official Partner ITBFX Start Trading
0 0 0
Devamını Oku
Yorum Yap
Kaynak: GlobeNewsWire Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Martin Marietta Receives Regulatory Approvals for Lhoist North America Transaction

Martin Marietta Receives Regulatory Approvals for Lhoist North America Transaction

RALEIGH, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Martin Marietta Materials, Inc. (NYSE: MLM) (Martin Marietta or the Company), today announced that it has received all necessary regulatory approvals for its previously announced combination with Lhoist North America, Inc. (LNA). The transaction is now expected to close in the third quarter of 2026, subject to customary closing conditions.

İlgili Semboller 1
MLM MLM
Kaynak: GlobeNewsWire
Kaynağı Ziyaret Et
0 0 0
Devamını Oku
Yorum Yap